IGCS19-0153

**CAN SENTINEL LYMPH NODE BIOPSY PREDICT PARAMETRAL INVOLVEMENT IN EARLY-STAGE CERVICAL CANCER?**

V Balay*, 1H Bonsang-Kitzis, 1L Magaud, 1M Deloménie, 1HT Nguyen-Xuan, 1M Koual, 1R Montero Macias, 1C Ngo, 1AS Bats, 2P Mathewet, 2F Lécuru, 1Georges Pompidou European Hospital, Gynecologic and Breast Oncologic Surgery Department, Paris, France; 2Hospices Civils de Lyon, Pôle IMER, Lyon, France; 2Lausanne University Hospital, Gynecology Department, Paris, France.

10.1136/ijgc-2019-IGCS.35

**Objectives** The purpose of this study was to identify patients with low-risk of parametrial involvement (PI) in early-stage cervical cancer potentially eligible for less radical surgery based on sentinel lymph node (SLN) status.

**Methods** We performed an ancillary analysis of data from two prospective trials on sentinel node biopsy for cervical cancer (SENTICOL I & II). Patients with FIGO IA-IIA cervical cancer treated with radical surgery and lymph node dissection, including SLN biopsy, were identified between 2005 and 2012 from 25 French oncologic centers. Patients who did not undergo radical surgery and patients who had preoperative brachytherapy were excluded.

**Results** Of 211 patients who fulfilled inclusion criteria, 11 patients (5.2%) had a pathological PI and 29 patients (13.7%) had positive SLN. The mean age was 43.2 years (range 22–85). 160 patients had a radical hysterectomy (75.8%) and 59 a radical trachelectomy (24.2%). 86.1% of patients had stage IB1 disease. There were 68.9% epidermoid carcinomas and 28.6% adenocarcinomas. On multivariate analysis, PI was significantly associated with tumor size ≥20 mm at preoperative MRI (ORa = 5.75, 95%IC = [1.17–28.32], p =0.03) and positive sentinel lymph node (ORa = 9.59, 95%IC = [1.13–41.43], p =0.02). Of 114 patients with tumor smaller than 2 cm at preoperative MRI and negative SLN, only one had parametrial involvement (0.9%).

**Conclusions** Patients at low-risk of parametrial involvement may be safely selected with simple criteria. Less radical surgery associated with SLN biopsy may be a promising option for patients with tumor smaller than 2 cm and negative SLN.

IGCS19-0392

**REducing overtreatment of early stage ovarian cancer: strategies implementation by a mirna-driven prognostic assessment**

A Ditto*, 1F Raspagliesi, 1U Leone Roberti Maggiore, 1V Chiappa, 1V Bogani, 1V Liberale, 1MT Evangelista, 1C Sonetto, 1G Maltese, 1F Zanaboni, 1Ml Carganju, 1B Paolini, 1D Mezzanzanica, 1P Alberi, 1F Murgia, 1A Tomassetti, 1L De Cesco, 1A Devecchi, 1M Bagnoli, 1IRCCS Foundation National Cancer Institute, Department of Gynecologic Oncology, Milan, Italy; 2IRCCS Foundation National Cancer Institute, Department of Diagnostic Pathology and Laboratory, Milan, Italy; 3IRCCS Foundation National Cancer Institute, Unit of Molecular Therapies- Department of Research, Milan, Italy; 4IRCCS Foundation National Cancer Institute, Integrated Biology Platform- Department of Applied Research and Technology Development, Milan, Italy.

10.1136/ijgc-2019-IGCS.37

**Objectives** About 30% of Epithelial Ovarian Cancer (EOC) patients present with early-stage disease (FIGO stage I-II). However, in spite of the generally favourable prognosis, eEOC have heterogeneous risk of relapse, ranging from 13% to over 40% in various reports. We previously identified 35 miRNAs that predicted risk of progression or relapse in advanced EOC and used them to create a prognostic model, the 35-miRNA-based predictor of Risk of Ovarian Cancer Relapse or progression (MiROvaR). The aim of the current study is to test MiROvaR performance to predict risk of progression or relapse in patients with eEOC.

**Methods** Patients with eEOC who underwent primary surgery at our Institution between 1994 and 2014 were included. The primary endpoint was progression-free survival. In particular, it was assessed the ability of MiROvaR to predict progression-free survival with Kaplan-Meier curves and the log-rank test.

**Results** A total of 80 patients were included in the study with a median follow-up time of 68.2 months (CI: 61.3–80.7).
Methods
Following consent, archival tissue was screened for AR+ by IHC with ≥5% considered positive. Enrolled patients were treated with enzalutamide 160mg po daily until progression of disease or treatment discontinuation. A cycle was 28 days. Adverse events were graded by CTCAE V 4.0.

Results
Between 11/2013–7/2018 160 patients were screened and 59 patients [45 high grade serous(HGS), 14 low grade serous(LGS)] consented to treatment on the study (1 patient was replaced; efficacy cohort=58, safety cohort=59). There was 1 confirmed and 1 unconfirmed partial response (PR), PFS6 was 22% (90% CI: 15.1–100%) with PFS6 for those with HGS 19.8% (90% CI: 12.7–100%) and for LGS 38.5% (21.7%-100%). Median PFS was 3.5 months. There were no toxicities >grade 3 related to study drug. Related grade 3 toxicities occurred in 6 patients [fatigue (1), rash (2), hypertension (1), anemia (1), and transaminase elevation (1)].

Conclusions
The study met its primary endpoint, with 13 patients (22%) remaining progression free at 6 months, however the response rate was low. Enzalutamide was well tolerated and may offer a good treatment option in select patients.

IGCS19-0345

INTERIM ANALYSIS OF OVARIAN CANCER BY THE US NATIONAL CANCER MOONSHOT’S TRI-FEDERAL (DOD/NCI/VA) APPLIED PROTEOGENOMIC ORGANIZATIONAL LEARNING AND OUTCOMES (APOLLO) RESEARCH NETWORK

1^1^Gl Maxwell*, 2^2^NW Bateman, 3^3^AR Soltis, 4^4^G Wang, 5^5^CL Daigard, 6^6^EF Petricoin, 7^7^CM Tarney, 8^8^C Rojas, 9^9^L Havrilesky, 10^10^DE Cohn, 11^11^JM Wells, 12^12^H Hu, 13^13^CA Hamilton, 14^14^CD Shriver, 15^15^M Wilkerson, 16^16^V Casablanca, 17^17^K Daroy, 18^18^TP Conrads. 1^1^Nova Women’s Hospital- the Inova Women’s Service Line- and the Inova Schar Cancer Center, The Women’s Health Integrated Research Center and the Department of Obstetrics and Gynecology, Falls Church, USA; 2^2^The John P Murtha Cancer Center- the Uniformed Services University of the Health Sciences- and Walter Reed National Military Medical Center, Gynecologic Cancer Center of Excellence, Bethesda- MD, USA; 3^3^The Henry M. Jackson Foundation for the Advancement of Military Medicine, Gynecologic Cancer Center of Excellence, Bethesda- MD, USA; 4^4^Uniformed Services University of the Health Sciences, The American Genome Center, Bethesda- MD, USA; 5^5^George Mason University, Applied Center for Proteogenomics, Manassas- VA, USA; 6^6^Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Division of Gynecologic Oncology, Bethesda- MD, USA; 7^7^Duke University Medical Center, Division of Gynecologic Oncology, Durham- NC, USA; 8^8^The James Comprehensive Cancer Center and Ohio State University, Division of Gynecologic Oncology, Columbus- OH, USA; 9^9^Walter Reed National Military Medical Center, Department of Pathology, Bethesda- MD, USA; 10^10^Chan Soon-Shiong Institute of Molecular Medicine, Department of Bioinformatics, Windber- PA, USA; 11^11^Uniformed Services University of the Health Sciences, John P Murtha Cancer Center, Bethesda- MD, USA; 12^12^Walter Reed National Military Medical Center, Division of Gynecologic Oncology, Bethesda- MD, USA.

Abstract 37 Figure 1 Kaplan-Meier curves of PFS in eEOC cohort according to MiROvaR classification

MiROvaR classified 37 patients (46.3%) at high-risk (14 events, median PFS: 117 months, 95%CI: 62-nyr) and 43 patients (53.7%) at low-risk of relapse (2 events, median PFS time: nyr; 95%CI: nyr). Kaplan-Meier curves confirmed the significantly different PFS time (figure 1) for the two groups with HR=10.13 (95%CI: 2.3–4.4, p=0.00015) for the high-risk patients.

Conclusions
MiROvaR confirmed as a potential predictor of EOC progression and has prognostic value independent of relevant clinical covariates also in patients with eEOC. MiROvaR warrants further investigation for the development of a clinical-grade prognostic assay.

IGCS19-0174

PHASE II STUDY OF ENZALUTAMIDE IN ANDROGEN RECEPTOR POSITIVE (AR+) RECURRENT OVARIAN CANCER: FINAL RESULTS

1^1^R Grisham*, 2^2^D Giri, 3^3^M Henson, 4^4^A Iasonos, 5^5^Q Zhou, 6^6^A McDonnell, 7^7^J Gishman, 8^8^R O’Cearbhaill, 9^9^D Zamarin, 10^10^C Aghajanian. 1^1^Memorial Sloan Kettering Cancer Center, Department of Medicine- Gynecologic Medical Oncology, New York, USA; 2^2^Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, USA; 3^3^Memorial Sloan Kettering Cancer Center, Department of Medicine- Gynecologic Medical Oncology Service, New York, USA; 4^4^Memorial Sloan Kettering Cancer Center, Department of Statistics, New York, USA; 5^5^Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, USA.

Abstract 37 Figure 1 Kaplan-Meier curves of PFS in eEOC cohort according to MiROvaR classification

10.1136/ijgc-2019-IGCS.38

Objectives
This was a single institution, phase II, Simon 2-stage with safety lead-in study of the oral androgen-receptor antagonist, enzalutamide, in patients with recurrent AR+ ovarian cancer with measurable disease and 1–3 prior lines of chemotherapy. The primary objective was to determine the proportion of patients surviving progression free for 6 months (PFS6) and overall response rate by RECIST 1.1 Criteria; with 7/58 responses or PFS6 of 13 being considered a positive study.

IGCS19-0345

INTERIM ANALYSIS OF OVARIAN CANCER BY THE US NATIONAL CANCER MOONSHOT’S TRI-FEDERAL (DOD/NCI/VA) APPLIED PROTEOGENOMIC ORGANIZATIONAL LEARNING AND OUTCOMES (APOLLO) RESEARCH NETWORK

1^1^Gl Maxwell*, 2^2^NW Bateman, 3^3^AR Soltis, 4^4^G Wang, 5^5^CL Daigard, 6^6^EF Petricoin, 7^7^CM Tarney, 8^8^C Rojas, 9^9^L Havrilesky, 10^10^DE Cohn, 11^11^JM Wells, 12^12^H Hu, 13^13^CA Hamilton, 14^14^CD Shriver, 15^15^M Wilkerson, 16^16^V Casablanca, 17^17^K Daroy, 18^18^TP Conrads. 1^1^Nova Women’s Hospital- the Inova Women’s Service Line- and the Inova Schar Cancer Center, The Women’s Health Integrated Research Center and the Department of Obstetrics and Gynecology, Falls Church, USA; 2^2^The John P Murtha Cancer Center- the Uniformed Services University of the Health Sciences- and Walter Reed National Military Medical Center, Gynecologic Cancer Center of Excellence, Bethesda- MD, USA; 3^3^The Henry M. Jackson Foundation for the Advancement of Military Medicine, Gynecologic Cancer Center of Excellence, Bethesda- MD, USA; 4^4^Uniformed Services University of the Health Sciences, The American Genome Center, Bethesda- MD, USA; 5^5^George Mason University, Applied Center for Proteogenomics, Manassas- VA, USA; 6^6^Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Division of Gynecologic Oncology, Bethesda- MD, USA; 7^7^Duke University Medical Center, Division of Gynecologic Oncology, Durham- NC, USA; 8^8^The James Comprehensive Cancer Center and Ohio State University, Division of Gynecologic Oncology, Columbus- OH, USA; 9^9^Walter Reed National Military Medical Center, Department of Pathology, Bethesda- MD, USA; 10^10^Chan Soon-Shiong Institute of Molecular Medicine, Department of Bioinformatics, Windber- PA, USA; 11^11^Uniformed Services University of the Health Sciences, John P Murtha Cancer Center, Bethesda- MD, USA; 12^12^Walter Reed National Military Medical Center, Division of Gynecologic Oncology, Bethesda- MD, USA.

Abstract 37 Figure 1 Kaplan-Meier curves of PFS in eEOC cohort according to MiROvaR classification

10.1136/ijgc-2019-IGCS.38

Objectives
This was a single institution, phase II, Simon 2-stage with safety lead-in study of the oral androgen-receptor antagonist, enzalutamide, in patients with recurrent AR+ ovarian cancer with measurable disease and 1–3 prior lines of chemotherapy. The primary objective was to determine the proportion of patients surviving progression free for 6 months (PFS6) and overall response rate by RECIST 1.1 Criteria; with 7/58 responses or PFS6 of 13 being considered a positive study.